• SB 431542: Precision ALK5 Inhibition in iPSC-Derived Neuron

  2026-06-11

  Explore how SB 431542, a selective ALK5 inhibitor, enables advanced TGF-β signaling research in human iPSC-derived neuron systems. Gain actionable insight into protocol design, assay interpretation, and unique cross-disciplinary applications.

• Z-VEID-FMK: Precision Caspase-6 Inhibitor for Apoptosis Assa

  2026-06-10

  Z-VEID-FMK empowers researchers to dissect caspase-6-dependent apoptotic pathways with unmatched selectivity. Its robust, irreversible inhibition and compatibility with complex cell models make it the gold standard for apoptosis and neurodegeneration studies.

• Norovirus Exploits NINJ1 for Selective Viral Protein Secreti

  2026-06-10

  This study demonstrates that murine norovirus hijacks the host protein NINJ1 to selectively secrete its NS1 protein, revealing a previously unrecognized mechanism for regulated protein export during infection. The findings establish a mechanistic link between apoptosis, membrane rupture, and unconventional viral protein secretion, offering new insights into host-pathogen interactions and cell death pathways.

• Lumiracoxib: Selective COX-2 Inhibitor for Muscle Injury Mod

  2026-06-09

  Lumiracoxib enables precise, temporal control of cyclooxygenase-2 pathway inhibition in muscle injury and revascularization models. Its high selectivity, robust solubility, and data-backed protocol parameters position it as an essential tool for dissecting inflammation and angiogenesis mechanisms—especially in venom-induced tissue models.

• Bcl-xL Maintains Quiescence for Survival in Pancreatic Cance

  2026-06-09

  Sela et al. reveal that Bcl-xL enforces a slow-cycling, chemoresistant state in nutrient-deprived pancreatic cancer cells. Their integrative approach distinguishes the essential survival mechanisms of quiescent tumor populations, informing combinatorial strategies for targeting tumor heterogeneity.

• circRHOBTB3 Restricts Prostate Cancer via NONO-MAOA Axis Mod

  2026-06-08

  The referenced Cancer Letters study identifies circRHOBTB3 as a tumor suppressor in metastatic prostate cancer, revealing its mechanism of action through cytoplasmic retention of NONO and downstream repression of MAOA expression. This work advances the understanding of circRNA-mediated regulation in cancer progression and suggests new biomarker and therapeutic strategies.

• Deferiprone in Enterocyte Metabolism: Protocols & Innovation

  2026-06-08

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) enables researchers to precisely induce iron deficiency and dissect iron-dependent pathways in intestinal and cancer models. This guide translates cutting-edge transcriptomic and metabolomics findings into actionable workflows, offering troubleshooting insights for reproducible results.

• Hoechst 33342/PI Double Staining Kit: Advanced Apoptosis Ana

  2026-06-07

  Explore the Hoechst 33342/PI Double Staining Kit for precise detection of apoptosis and necrosis using advanced fluorescent techniques. This article reveals unique scientific applications and deep dives into recent research linking chromatin condensation and membrane integrity assays.

• CARMIL Membrane-Binding Domain: Mechanisms in Actin Assembly

  2026-06-06

  This study clarifies how the membrane-binding (MB) domain of CARMIL regulates capping protein (CP) activity and actin filament assembly at the plasma membrane. By identifying the MB domain's dual roles in targeting and releasing CP, the findings refine current models of actin regulation and have practical implications for dissecting protein-protein interactions in cytoskeletal research.

• Captopril in Translational Research: ACE Inhibitor Workflows

  2026-06-05

  Captopril stands out as a gold-standard ACE inhibitor for dissecting hypertension, gastrointestinal motility, and oncology pathways. This article delivers actionable protocols, troubleshooting strategies, and the latest translational insights—including bradykinin pathway modulation—empowering researchers to maximize APExBIO’s high-purity Captopril in cross-domain bench applications.

• Phebestin as a Potent Antiplasmodial Aminopeptidase Inhibito

  2026-06-05

  The reference study introduces phebestin, a bestatin-related aminopeptidase inhibitor, and demonstrates its nanomolar efficacy against both chloroquine-sensitive and resistant Plasmodium falciparum strains. These findings suggest phebestin as a promising candidate for antimalarial drug development, with implications for overcoming current therapeutic resistance.

• Workflow Guide: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl

  2026-06-04

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a high-purity research tool for inhibition of hypoxia-inducible factor 1 transcriptional activity, supporting workflows in cancer biology, angiogenesis, and apoptosis research. This compound should not be used in diagnostic or therapeutic applications and is optimized for controlled laboratory settings.

• Disodium Bicinchoninate: Advanced Aqueous Reagent for Oxidat

  2026-06-04

  Explore how Disodium bicinchoninate (sodium [2,2'-biquinoline]-4,4'-dicarboxylate) enables next-generation oxidative stress and inflammation assays in molecular biology. This article uniquely connects robust chemical properties to practical, high-reproducibility research workflows.

• AMPK Suppresses Autophagy: Rethinking Energy Stress Response

  2026-06-03

  A recent study overturns the longstanding view that AMPK induces autophagy in energy-stressed cells, showing instead that AMPK inhibits autophagy initiation via ULK1 suppression. This insight reshapes experimental strategies for dissecting metabolic signaling pathways, with implications for how researchers deploy tools like Nicotinamide Adenine Dinucleotide (NAD+) in cellular energy stress models.

• FAISL lncRNA Blocks FAK Degradation to Promote TNBC Progress

  2026-06-03

  The reference study identifies the lncRNA FAISL as a critical regulator of FAK protein stability in triple negative breast cancer (TNBC), revealing that FAISL inhibits Calpain 2-mediated proteolysis of FAK to drive tumor growth and metastasis. This work uncovers a lncRNA-driven mechanism in TNBC progression and highlights the potential of targeting FAISL for therapeutic intervention.

451 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page